<DOC>
	<DOC>NCT00504543</DOC>
	<brief_summary>This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criteria Male and female patients 18 years or older Recipients of first kidney transplant from a deceased or living not related donor Exclusion criteria Need for medication prohibited in the study Patients with heart disease (own or family history) Patients or donor HIV, Hepatitis B (HBsAg) or Hepatitis C (HCV) positive Patients with high immunological risks Patients with a history of cancer Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Kidney transplant, AEB071</keyword>
</DOC>